GLP-1 Receptor Agonists and Cirrhosis in Meta...

Interview with Robert Goulden, MBBS author of Magnesium Supplementation and Tachyarrhythmias:A Nonrandomized Clinical Trial and Jason H. Wasfy, MD, MPhil author of Evidence for Clinical Treatment Decisions Without Randomized Data. Hosted by Ilana Richman, MD MHS. Related Content: ...  Show more

Interview with Giselle Corbie, MD, MSc, Associate Editor of JAMA Internal Medicine, and Lynda H. Powell, PhD, author of Lifestyle Intervention for Sustained Remission of Metabolic Syndrome: A Randomized Clinical Trial. Hosted by Eve Rittenberg, MD. Related Content: Lifestyle Inte ...  Show more

Interview with Bradley J. Katz, MD, PhD, author of Ophthalmic Complications Associated With the Antidiabetic Drugs Semaglutide and Tirzepatide. Hosted by Neil Bressler, MD. Related Content: Ophthalmic Complications Associated With the Antidiabetic Drugs Semaglutide and Tirzepatid ...  Show more

Contributor: Travis Barlock MD

Educational Pearls:

How do you differentiate between compensated and decompensated cirrhosis?

Use the acronym VIBE to look for signs o ...

By the end of this episode you will be able to: Describe the anatomy and physiology of the liver Outline the pathophysiology and common symptoms of liver failure Explain how to assess and treat a patient with cirrhosis 

<div>Metabolic dysfunction-associated steatotic liver disease (MASLD), also known as Non-alcoholic fatty liver disease (NAFLD), is estimated to affect up to 1 in 5 people in the UK. Rates are increasing with rising levels of obesity. Although most cases of MASLD are linked to exc ...  Show more